An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
Brief description of study
If you have been diagnosed with colorectal cancer that has not yet been treated and has spread to other parts of your body, you may qualify for this Phase 2/3 study. The main goal of this study is is to characterize the effectiveness (how well the drug works) of nivolumab in combination with standard of care (bevacizumab plus a standard chemotherapy regimen consisting of Oxalipiatin, Leucovorin and fluorouracil also known as FOLFOXB) when diagnosed wit metastatic colorectal cancer by comparing it to the effectiveness seen in participants treated with the standard of care alone (bevacizumab plus mFOLFOX6).
Clinical Study Identifier: s18-00299
ClinicalTrials.gov Identifier: NCTs18-00299
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
